Medifast Inc Q3 FY2025 Earnings Call

Greetings, and welcome to the Medifast Third Quarter 2025 Earnings Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steve Zenker, Vice President of Investor Relations. Thank you, sir. You may begin.

Good afternoon, and welcome to Medifast's Third Quarter 2025 Earnings Conference Call. On the call with me today are Dan Chard, Chairman and Chief Executive Officer; and Jim Maloney, Chief Financial Officer. By now, everyone should have access to the earnings release for the third quarter ended September 30, 2025, that went out this afternoon at approximately 4:05 p.m. Eastern Time. If you have not received the release, it is available on the Investor Relations portion of Medifast website at www.medifastinc.com. This call is being webcast, and a replay will also be available on the company's website. Before we begin, we would like to remind everyone that today's prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. The words believe, expect, anticipate and other similar expressions generally identify forward-looking statements. These statements do not guarantee future performance and therefore, undue reliance should not be placed on them. Actual results could differ materially from those projected in any forward-looking statements. All of the forward-looking statements contained herein speak only as of the date of this call. Medifast assumes no obligation to update any forward-looking statements that may be made in today's release or call. Now I would like to turn the call over to Medifast's Chairman and Chief Executive Officer, Dan Chard.

Thank you, Steve, and good afternoon, everyone. We appreciate you joining us today as we discuss our third quarter results and share an update on our progress. This is an important year for Medifast, one where the work we've done to transform the business is beginning to align more clearly with the opportunity we see in front of us. The weight loss and wellness industry has undergone fundamental change in a very short time. The rapid growth in consumer understanding and usage of GLP-1 medications has reshaped much of the public conversation around obesity and health, introducing millions of people to a tool for appetite control that leads to weight loss. While these medications are truly groundbreaking, they are not a complete solution to long-term health unless they are paired with lifestyle modifications. Further, most weight challenges are rooted in poor metabolic health, also called metabolic dysfunction, which medication alone does not fully correct. A lifestyle approach that builds healthy habits and protects lean muscle mass during weight loss is essential to improving metabolic health. Since many people discontinue medication, the absence of these fundamental changes often leads to weight regain. For most people, the most durable path forward comes from addressing the underlying metabolic issues, not relying on medication alone. Data across multiple studies paint a consistent picture, up to 40% of the weight loss while on GLP-1 medications comes from lean mass, including muscle. 74% of those on the medications discontinue them within a year and the majority regain much of the weight they lost once they stop. For many, this leads to a cycle of temporary success followed by intense frustration. The opportunity for Medifast is to help break that cycle to empower people not just to lose weight, but to learn how to keep it off and most importantly, to improve their metabolic health in the process, leading to a body that uses energy more efficiently, preserves muscle and functions the way it was designed to. There is a significant opportunity in front of us to deliver a reset that helps the body work as it was meant to. More than 90% of U.S. adults are metabolically unhealthy. This represents not only a vast health challenge but also a once-in-a-generation opportunity to redefine what wellness looks like. Our mission and our growth strategy are centered on meeting that need. Our clinically study plan is designed to address the underlying causes of metabolic dysfunction, reducing bad visceral fat, retaining lean mass, and protecting healthy muscle while helping improve overall body composition. We don't believe success should be measured just by pounds lost but by how much healthier a person's body becomes in the process. We recently announced clinical research findings led by our scientific and clinical affairs team using a science focused on metabolic synchronization, a breakthrough approach that reverses metabolic dysfunction with a targeted reset. Our most recent clinical analysis uncovered findings that revealed that our comprehensive plan delivers strong and targeted fat burn resulting in not only weight loss but also improved body composition. At 16 weeks, clients on our plan retained 98% of their lean mass, reduced visceral fat by 14%, and showed measurable improvement in body composition while losing weight and protecting muscle. This reduction in visceral fat, the bad fat driving metabolic dysfunction, along with strong muscle preservation are key indicators of improved metabolic health. Whether a client is using a GLP-1 medication, transitioning off one, or not using one at all, our program provides a foundation for overall metabolic health and well-being. This is not just a short-term fix, but a comprehensive system that is specifically designed to help people live a healthier life. At the center of our approach is the human connection provided by our incredible coaches. These coaches play a vital role in translating the underlying science that powers our approach into real-world results that help people make a real difference in their approach to health. Coaches' understanding of the benefits and shortcomings of GLP-1 medications continues to build all the time. Currently, 61% of our coaches have already worked with clients who are using GLP-1 medications, and 22% of our client base reports either using or having tried a GLP-1 medication in the past year. That gives us invaluable insight into how these medications are being used and how our approach can complement them. Medications alone are simply not enough in our view. Clinical data shows that clients who work with a coach lose 10x more weight and 17x more fat than those who go it alone. That's certainly not a coincidence. Our coaches guide clients through the important behavioral and nutritional lifestyle changes needed to maintain their progress on their health journey. The coach has helped people stay accountable, navigate challenges, and build the healthy lifestyle habits that lead to lasting results. Coaching is what makes the difference between temporary change and long-term transformation. We're evolving Medifast from being seen primarily as a weight loss company to one that is recognized as a leader in the broader field of metabolic health. It's a shift to a far larger and more durable market as we move from helping people not only lose weight but also helping them live metabolically healthier lives. Looking ahead, the company plans to launch significant product innovations using the science of metabolic synchronization and incorporating next-generation ingredients for metabolic enhancement. Initial feedback from the field of coaches has shown encouraging results and we expect to bring this new product line to market next year. This new product line builds on the strength of our existing programs, and we believe it will further differentiate Medifast in the marketplace. Our aim is not just to respond to the rise of GLP-1s, but to define what the next generation of metabolic health solutions will look like, combining clinical credibility, human connection, and healthy results. To deliver further on our ambitions in the metabolic health space, we're moving forward on several fronts. Our coach leaders have already been trained on the new clinical data and they are now cascading that knowledge throughout their organizations. This training will continue into 2026 as coaches learn to reach new types of clients, people who are focused not just on weight loss but also on their overall metabolic health. We are seeing continued momentum in our work to support our coaches and clients. The new Premier+ pricing and auto-ship program has simplified our value proposition, creating a more consistent experience for both coaches and clients. It offers immediate savings, predictable pricing, and a straightforward path to loyalty, making it easier for coaches to attract and retain clients. While it's still early, we're encouraged by the initial response which has shown an uptick in baseline client retention beyond the first month. We've also continued to strengthen the leadership foundation of our field through our EDGE leadership development program. EDGE combines incentives, best practices, and recognition tools to help coaches grow their businesses with purpose and structure. The program was built in partnership with field leaders ensuring it reflects real-world experience. It's designed to make early success achievable and sustainable, helping new coaches find their footing and build confidence and enabling our experienced coaches to scale their impact. In a world where technology increasingly replaces human interaction, our greatest strength remains the power of personal connection, and we're continuing to focus on how we take full advantage of our highly personalized solutions. Both Premier+ and EDGE are important components of our commercial model, and we expect these to play a central role in continuing to improve coach productivity and stability as we move into 2026. In the third quarter, productivity among active coaches continued to show signs of stability. We're also continuing to invest in our digital platforms to make the coaching and client experience even more seamless. Enhancements to our app and reporting tools are providing better visibility into client progress and coach performance, giving our field more actionable insights and allowing them to focus where they can make the biggest impact. Regarding our third quarter results, revenue of $89 million for our third quarter was at the high end of our guidance range and EPS came in within our guidance range. Active earning coach productivity for the quarter of $4,585 was down just 2% year-over-year, continuing a trend of moderating declines. Sequentially, coach productivity was down 1%. As we look ahead, our strategy remains clear. We're building Medifast as a science-backed coach-guided system for promoting long-term metabolic health. The trends shaping this industry from medical intervention to lifestyle integration point towards the need for exactly what we offer, a system that helps people improve their metabolic function by getting rid of the bad fat, preserving lean mass, and protecting their muscle, ultimately empowering them to healthier results over time. We've already taken important steps to position the business for this future. Our transformation is not theoretical. It's visible in the way our coaches are working and the science behind our products and in the foundation we're laying for the next phase of growth. We have more work to do, but we're confident in our direction. We have a strong balance sheet, no debt, and more than $170 million in cash and investments. We have a passionate coach community that continues to adapt and lead, and we have a comprehensive program, plan, and product that are scientifically validated and aligned with where we believe consumer demand is headed. We're a company that has been built on ongoing innovation and that is always thinking about the next chapter. We expect that the foundation we're building today will redefine what health looks like for the years to come. By combining our science, our coaches, and our community, we are positioning Medifast to become the trusted partner for millions of people seeking to improve metabolic health. We're building for long-term sustainable growth, and we're doing that with discipline and conviction. Now I'll turn it over to Jim to review the finances and our outlook for the next quarter.

Thank you, Dan. Good afternoon, everyone. As Dan mentioned earlier, third quarter 2025 results for both revenue and EPS were at the high end of our guidance ranges. Revenue for the third quarter was $89.4 million, a decrease of 36.2% versus the year earlier period, primarily due to a decrease in the number of active earning OPTAVIA coaches. We ended the quarter with approximately 19,500 active earning OPTAVIA coaches, a decrease of 35% from the third quarter of 2024. Average revenue per active earning OPTAVIA coach for the third quarter was $4,585, a year-over-year decrease of 1.9%, primarily driven by continued pressure on client acquisition. We continue to see moderating year-over-year declines in this key metric. Gross profit decreased 41.2% year-over-year to $62.2 million driven by lower sales volumes, partially offset by lower cost of sales. Gross profit margin for the current quarter was 69.5%, which decreased 590 basis points compared to the year earlier period, attributable to 450 basis points of loss of leverage on fixed costs and 180 basis points of a reserve for the reformulation of the Essential product line. As Dan mentioned, we expect to introduce a new product line next year which is intended to improve upon the effectiveness of our current essential product line in addressing overall metabolic health. These new products will replace the current Essential line of fuelings that are part of many of our current plans. SG&A expense was down 36% year-over-year to $66.2 million primarily due to a $19.7 million decrease in coach compensation on fewer active earning coaches and lower volumes. Additionally, SG&A expenses in the current quarter reflected decreases of $5.6 million related to company-led marketing compared to 2024, as well as $2.9 million for the company's convention costs and $2 million for the company's collaboration with LifeMD that did not recur in the current quarter. SG&A as a percentage of revenue increased 20 basis points, primarily due to approximately 520 basis points associated with the loss of leverage on fixed costs and other smaller increases, partially offset by a 360 basis point reduction related to company-led marketing and 210 basis points for the company's convention costs incurred in the prior year's comparable period that did not recur in the third quarter of 2025. Loss from operations was $4.1 million in the third quarter of 2025 compared to income from operations of $2.1 million in the prior year comparable period. As a percentage of revenue, loss from operations was 4.6% in the third quarter compared to income from operations of 1.5% in the prior year period. Other income increased $2 million year-over-year to $1.4 million, primarily due to a loss on the company's investment in LifeMD's common stock during the corresponding period in 2024. As you may recall, we sold the investment in the second quarter of 2025. The effective tax rate was 14.9% for the third quarter of 2025 compared to 28.5% in the prior year period. The change in the effective tax rate for the 3 months ended September 30, 2025, was primarily driven by a decrease in the tax benefit of research and development tax credits which represented 115.3% of the change, partially offset by an increase of 85.6% from the impact of state taxes. These percentages were magnified by the near breakeven pretax position in the current year. Net loss in the third quarter of 2025 was $2.3 million or $0.21 loss per diluted share compared to net income of $1.1 million or $0.10 per share in the year-earlier period. Our financial position remains strong with $173.5 million in cash, cash equivalents, and investments and no interest-bearing debt as of September 30, 2025. Now I'll turn to guidance. We are expecting fourth quarter revenue to range from $65 million to $80 million and a loss per share for the quarter ranging from $0.70 to $1.25.

Our first question comes from Jim Salera with Stephens.

I wanted to first start with the shifting focus towards metabolic dysfunction and how integrating that messaging with the coaches is going to work. Can you just maybe walk us through the process to make sure that you have consistent messaging among the coaches and that they're all kind of trained up on the new go-to-market or strategy around communicating the kind of holistic view that you guys are taking to weight loss moving forward?

Sure, Jim. I want to mention that Nick Johnson, our Chief Field Operations Officer and President of OPTAVIA, is also here with us. I'll share a few comments and then let him speak about our efforts to ensure that coaches nationwide are properly trained and informed about our new approach to metabolic health. Firstly, most weight loss issues and the majority of leading health challenges in the country are linked to metabolic health, also known as metabolic dysfunction. Our coaches understand this, so the foundation is awareness. We have conducted a significant study that builds on our previous research and delves deeper into clinical studies to demonstrate what our program achieves for metabolic health and its ability to reverse metabolic dysfunction, which in turn relates to weight loss. We covered some of our study’s findings in the last call, but I’ll reiterate them. The most important finding is that our program targets harmful fat, often called visceral fat, which accumulates around the belly and essential organs, and it significantly reduces this fat. It also helps maintain 98% of lean mass during weight loss, safeguards muscle, and enhances body composition. Additionally, when a coach supports someone on the program, clients are able to lose ten times more weight and seventeen times more fat. These are new insights we've shared with our coaches. The core of what they are doing now involves targeting, which is quite critical, as 90% of Americans are metabolically unhealthy or experiencing metabolic dysfunction. With this research and a clear understanding of how to reverse these conditions, they have a compelling and essential new narrative. This is particularly significant in light of the impact of GLP-1 drugs on individuals. Our program stands out by preserving 98% of lean body mass, while GLP-1 drugs can lead to 40% of weight loss coming from lean mass and high discontinuation rates, with 74% of patients ceasing usage within a year and two-thirds of the weight being regained. This outlines the problem and solution. Now, I’ll hand it over to Nick to discuss how we are training our leaders and how this leadership group is currently training the field.

So recently, we met with all of our leaders at a better retreat, our annual leadership retreat that took place in Sundance, Utah. All of those lines of business across our business were actually represented. So with all those leaders of the different lines of business now informed, trained and understand where we're going in the direction of the metabolic synchronization of proprietary science that addresses neuro versus metabolic dysfunction. From now until the end of the year, those messages, those trainings will continue to be disseminated. And so by the end of the year, we expect to have all of the different coaches all the way down to our core rank of Executive Director trained and steeped in this direction. So we ensure that we are across the network singing from the same song sheet, so to speak.

Great. That's very helpful. Can you speak to just the EDGE program and maybe the incentive structure as again, you kind of expand the aperture and the focus of what coaches are going to be communicating to potential clients? And I would imagine that kind of broadens the range of potential clients they can talk to.

Yes, it's another good one for Nick. So Nick, why don't you take that one as well?

Sure thing. So as we've talked about in the past, the EDGE program is designed around really three activities, and they're all based on the same core rank Executive Director. It's for creation of new executive directors, duplication of those directors, and then multiplication of those executive directors. So the EDGE program is designed to change the rank composition of the business. Now keep in mind that those executive directors have approximately $6,000 in revenue per Executive Director. They're highly, highly productive. So when we see the rank composition of the business start to shift in a more positive direction, revenue and therefore, productivity go up as the rank composition improves. So we'll continue to focus on the EDGE program, like we said in the past, focusing on becoming and duplicating and multiplying those executive directors.

Okay. That's helpful. Maybe shifting gears a little bit, Jim, I have a couple of questions regarding the guidance and some of the results from the quarter. To start, it seems like you have closed the gap between the decline in SG&A and the decline in the top line, which are now much more aligned than in previous quarters. I appreciate the details provided about some one-time expenses. Can you give us some insight on how we should consider that if the top line declines by a certain percentage, SG&A might underperform by 100 basis points or 200 basis points as we model this going forward?

Yes. As you mentioned, one of the expenses in Q3 was about $1.5 million related to the reformulation of our essential line, a decision we made in Q3 of 2025. We believe this will be a one-time cost. Additionally, we experienced a loss of leverage with fixed costs impacting our gross margin. We are committed to maintaining a strong balance sheet, finishing the quarter with $170 million in cash and investments. We took steps in October to align the business better in preparation for future growth, which we believe will lead to improved margins. Regarding our guidance, we anticipate ongoing pressure into Q4, aligning with what we've previously communicated. Our business's recovery to growth will depend on improving client acquisition and retention.

Okay. And maybe on the top line, can you just speak to any outside of, obviously, GLP-1 kind of well-covered trends just broader economic softness and softness we've seen in the consumer? Just any commentary you can offer on how that's been impacting the likelihood of consumers to add an incremental monthly expense like OPTAVIA into their budget?

We continue to observe that consumers prioritize their health, which has been an ongoing issue and shows no signs of diminishing. Our clients who engage with our program demonstrate high satisfaction, as reflected in their repeat usage. Regarding the impact of a challenging economy on consumer spending, I believe it certainly does have an effect. However, we still see consumers willing to invest in their health over other expenditures. This gives us a sense of optimism about our position. We have enhanced the value of our offerings by gaining deeper insights into how our program benefits end consumers. Our coaches are improving in their ability to operate effectively in the current landscape. Currently, over 60% of our coaches support at least one client using or having used a GLP-1 drug, with 22% of our client base actively involved with these medications. We believe our program remains valuable and relevant to individuals either using a GLP-1 drug or those who prefer to pursue a lifestyle program without it, whether due to personal choice or adverse reactions to the medication. Additionally, individuals transitioning off these drugs are focused on maintaining their health gains. This scenario provides further motivation for those seeking to address the underlying issues of metabolic dysfunction and achieve the lasting transformation that our coaches have been emphasizing for a long time.

Got it. And then maybe just one housekeeping question. Jim, I think you mentioned when you were breaking down the SG&A expenses that you were cycling a $2 million collaboration with LifeMD. I want to clarify, is that a one-time expense from last year that we're moving past or are you ending the LifeMD partnership and that will be a recurring item in SG&A?

No, the collaboration is ongoing. What that is, is that was the last in 2024, that $2 million was the last bit of amortization. If you remember, at the beginning of our collaboration, we invested $10 million into LifeMD as part of the collaboration. And that $2 million in Q3 of 2024 represented the last bit of the amortization. So we took the $8 million prior to that. So you won't see that any longer.

We have reached the end of our question-and-answer session. There are no further questions at this time. I would now like to turn the floor back over to Dan Chard for closing comments.

Thanks, everybody, for joining the call today. This continues to be a period of meaningful transformation, as you could hear for the company. And we're evolving with purpose to become a science-backed coach-led leader in metabolic health. Our approach built around the science of metabolic synchronization enables us to target better health rather than just weight loss, reducing visceral fat while preserving lean mass. We're very encouraged by the progress that we're making from the stabilization of coach productivity to advancing new product innovation and digital tools. We remain confident in our strategy, supported by a strong balance sheet and a dedicated coach community focused on long-term client success. I look forward to sharing even more when we present at the Stephens Annual Investment Conference on November 19 in Nashville. Thanks again for joining us today and for your continued interest in Medifast.

This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.